Connect Biopharma Holdings (CNTB) Net Margin (2024 - 2026)

Connect Biopharma Holdings (CNTB) posted Net Margin of 11478.11% for Q1 2026, up 89.32% sequentially from 107500.0% in Q3 2025.

Connect Biopharma Holdings (CNTB) Net Margin (2024 - 2026) Analysis & Trends

Connect Biopharma Holdings has reported Net Margin for 3 years, with the latest figure at 11478.11% in Q1 2026.

Quarterly Net Margin changed N/A year-over-year to 11478.11% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 27727.9% (changed N/A YoY) and the FY2025 annual result came in at 86687.5%, down 8662747.0% from the prior year.
Net Margin climbed to 11478.11% in Q1 2026 per CNTB's latest filing, from 107500.0% in the prior quarter.
Over five years, Net Margin peaked at 1056.28% in Q3 2024 and troughed at 107500.0% in Q3 2025.
A 3-year average of 29636.65% and a median of 11478.11% in 2026 frame the typical range for Net Margin.
The widest YoY moves for Net Margin: up 10644372 bps in 2025, down 10644372 bps in 2025.
Over 3 years, Net Margin stood at 1275.93% in 2024, then sank by 8325 bps to 107500.0% in 2025, then soared by 89 bps to 11478.11% in 2026.
According to Business Quant data, Net Margin over the past three periods registered 11478.11%, 107500.0%, and 26872.92% for Q1 2026, Q3 2025, and Q2 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Net Margin (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	32.99%
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	30.23%
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	31.16%
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	-539.31%
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	13.90%
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	12.74%
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	-3.12%
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	12.09%
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	-16.51%
10	Connect Biopharma Holdings	144.32 Mn	144.32 Mn	-	-624.42%

Download Data